CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
doi: 10.2196/jmir.1923
PMID: 22209829
* Required

Your name *
First Last
Carinne Brody

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
Touro University California
A Mobile Intervention to link Female Entertainment Workers in Cambodia to Health and Gender-based Violence Services: Randomized controlled trial

Mobile Link

v1

Khmer (Cambodian Language)

Your e-mail address *
abc@gmail.com
carinne.brody@gmail.com

Title of your manuscript *
Provide the (draft) title of your manuscript.

Name of your App/Software/Intervention *
If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

 Evaluated Version (if any)
e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Language(s) *
What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

URL of your Intervention Website or App
e.g. a direct link to the mobile app on appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

URL of an image/screenshot (optional)
Accessibility *
Can an enduser access the intervention presently?
- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Other:

Primary Medical Indication/Disease/Condition *
e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

sexual and reproductive health

Primary Outcomes measured in trial *
comma-separated list of primary outcomes reported in the trial

self-reported HIV and STI testing, condom use,

Secondary/other outcomes
Are there any other outcomes the intervention is expected to affect?

contact with outreach workers, escorted referral services use, forced drinking, and GBV experiences

Recommended "Dose" *
What do the instructions for users say on how often the app should be used?
- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Other:
Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Other:

Overall, was the app/intervention effective? *

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Other: no primary outcomes were significantly better, three secondary outcomes

Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Other:
### Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- [ ] not submitted yet / unclear where I will submit this
- [ ] Journal of Medical Internet Research (JMIR)
- [ ] JMIR mHealth and UHealth
- [ ] JMIR Serious Games
- [ ] JMIR Mental Health
- [ ] JMIR Public Health
- [ ] JMIR Formative Research
- [ ] Other JMIR sister journal
- [ ] Other:

### Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- [ ] Pilot/feasibility
- [x] Fully powered

### Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- [ ] no ms number (yet) / not (yet) submitted to / published in JMIR
- [ ] Other:

### TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase 'Randomized Controlled Trial'? (if not, explain the reason under 'other')

- [ ] yes
- [ ] Other:
1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use “web-based” and/or “mobile” and/or “electronic game” in the title. Avoid ambiguous terms like “online”, “virtual”, “interactive”. Use “Internet-based” only if intervention includes non-web-based Internet components (e.g. email), use “computer-based” or “electronic” only if offline products are used. Use “virtual” only in the context of “virtual reality” (3-D worlds). Use “online” only in the context of “online support groups”. Complement or substitute product names with broader terms for the class of products (such as “mobile” or “smart phone” instead of “iphone”), especially if the application runs on different platforms.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ● essential

Clear selection

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A Mobile Intervention to link Female Entertainment Workers in Cambodia to Health and Gender-based Violence Services: Randomized Controlled Trial"

1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., “with telephone support”).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Clear selection

Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., “for children with Type I Diabetes”) Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ● essential

Clear selection
1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions
NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

"Female Entertainment Workers in Cambodia"

1b-1) Key features/functionality/components of the intervention and comparator in the METHODS section of the ABSTRACT
Mention key features/functionality/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important 0 0 0 0 essential
Clear selection

Does your paper address subitem 1b-1? *
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study evaluates the Mobile Link intervention, aiming to improve FEWs’ health by connecting them to health services using automated twice-weekly short message services and voice messages with health information and direct links to outreach workers.” and “The control for this study received the existing standard care. Standard care included face-to-face counseling, free HIV and STI testing and condoms, and clinic phone numbers and hotline phone numbers with a toll-free help-line for clients staffed by trained counselors."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT
Clarify the level of human involvement in the abstract, e.g., use phrases like “fully automated” vs. “therapist/nurse/care provider/physician-assisted” (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important 0 0 0 0 essential
Clear selection
Does your paper address subitem 1b-ii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"automated twice-weekly short message services and voice messages"

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT
Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important 2 3 4 5 essential

Clear selection

Does your paper address subitem 1b-iii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The primary outcome measures included self-reported HIV and STI testing, condom use, and contraceptive use which we assessed through face-to-face structured interview."

1b-iv) RESULTS section in abstract must contain use data
Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important 2 3 4 5 essential

Clear selection

Does your paper address subitem 1b-iv?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We included 218 FEWs in intervention and 170 FEWs in control arms in the per-protocol analyses after 212 removing dropouts."

1b–v) CONCLUSIONS/DISCUSSION in abstract for negative trials
Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important ○ ○ ○ ◼ ○ essential

Does your paper address subitem 1b–v?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Longer-term messaging may increase access to services and impact FEWs' health outcomes in the future."

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution
Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

1 2 3 4 5
subitem not at all important ○ ○ ○ ◼ ○ essential

Does your paper address subitem 2a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The Mobile Link intervention is an mHealth project aiming to engage and connect young FEWs in Cambodia to existing prevention, care, and treatment services."
2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5

subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Health interventions using mobile phones – referred to as mobile health (mHealth) – presents a viable solution for connecting hard-to-reach, stigmatized, and criminalized populations such as FEWs to health services. In recent years, mHealth has received widespread attention due to its applicability in low-resource settings. mHealth has been used effectively in low- and middle-income countries to collect and report community health data [17], disperse health education information [17], raise health awareness [18], and conduct routine check-ins with patients and trigger follow-ups by nurses [19]. However, knowledge gaps persist in mHealth research. Fewer mHealth interventions have been rigorously evaluated. Much of the existing literature comprises small pilot studies lacking established health indicators and generalizability [20–22]. Additionally, there is a deficiency in mHealth research on interventions targeted towards behavior change and sexual and reproductive health (SRH) [21]."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"This study aims to evaluate the efficacy of the Mobile Link intervention in engaging FEWs, connecting them to existing HIV, SRH, and GBV services, and ultimately improving their health."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio
3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

"Protocol adaptations
There are several protocol deviations to note. The original protocol called for a 12-month (52 week) trial. However, due to high dropout rates at the midterm, we extended the trial to 60 weeks to recruit and enroll more participants who would have the chance to be exposed to the intervention for at least 30 weeks.

We did not anticipate the level of loss to follow-up that occurred and, therefore, did not have a plan in place for replacement recruitment in our original protocol. We decided to recruit replacement participants at the midline by randomly selecting FEWs from our master list from the same venue and age group. In our analyses, we defined exposure as having had at least 30 weeks of exposure to the intervention.

Another deviation occurred in our group assignment plan. Initially, we planned to randomize at the entertainment venue level to conduct a cluster RCT. Before the implementation, we changed our trial design to randomize at the individual level due to the high level of movement of FEWs between venues. As a result, we modeled intervention effects using the individual rather than the venue as the analysis unit. We computed clustered standard errors based on the venue rather than including the venue as a level in the mixed-effects outcome models. Finally, we included the venue type (e.g., karaoke bar, beer garden, etc.) as a covariate in all our models.

In our protocol, we planned to send out weekly survey questions to intervention participants on various health topics. During intervention development, we heard from pilot participants that they felt reluctant to give that type of information through the phone. We were also concerned about message fatigue, privacy, and literacy and decided to omit that part of the intervention.

Finally, in our protocol, we stated that we would present an ITT analysis. Because the ITT and per-protocol findings were the same, we decided to present

3b-1) Bug fixes, Downtimes, Content Changes
Bug fixes, Downtimes, Content Changes: eHealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | |
| essential | | | | |
4a) Eligibility criteria for participants

"The intervention's participant inclusion criteria included: (1) working at an entertainment venue in the study sites; (2) being currently sexually active, defined as having engaged in oral, vaginal, or anal sex in the past three months; (3) owning a mobile phone; (4) knowing how to retrieve VM or retrieve and read SMS; (5) self-identifying as a FEW; (6) willing to receive two SMS/VM per week for one year; (7) providing written informed consent; and (8) agreeing to a follow-up visit after six months and 12 months."

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

1 2 3 4 5
subitem not at all important 0 0 0 1 0 essential

Does your paper address subitem 4a-i?

Education level is included in Table 1. Knowing how to retrieve VM or retrieve and read SMS is an eligibility criteria.

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

1 2 3 4 5
subitem not at all important 0 0 0 0 1 essential

Does your paper address subitem 4a-ii?
4a-ii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

- [ ] 1: subitem not at all important
- [ ] 2: 3: 4: 5: essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"All participants were recruited in-person at the five study sites by trained Mobile Link lay community health workers."

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

- [ ] 1: subitem not at all important
- [ ] 2: 3: 4: 5: essential

Does your paper address subitem 4a-iii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Community health workers provided verbal information to FEWs regarding the Mobile Link's details because of low literacy rates in this population. Eligible FEWs signed the informed consent form."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The trial was conducted in two sites in Phnom Penh and one site each in Banteay Meanchey, Battambang, and Siem Reap. These provinces were selected because of substantial populations of FEWs and high HIV burdens."

4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

- [ ] 1: subitem not at all important
- [ ] 2: 3: 4: 5: essential

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The trial was conducted in two sites in Phnom Penh and one site each in Banteay Meanchey, Battambang, and Siem Reap. These provinces were selected because of substantial populations of FEWs and high HIV burdens."
Does your paper address subitem 4b-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study:

"The primary and secondary outcomes were tracked and measured using self-reported data from the baseline, midline, and endline surveys."

4b-ii) Report how institutional affiliations are displayed
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ● essential
Clear selection

Does your paper address subitem 4b-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study:

"Development of the message-based intervention was conducted with the support of local partners, InSTEDD iLab and the Women’s Media Center (WMC). InSTEDD developed the mobile platform for interactive message delivery and data management using an open-source software program. The WMC helped translate messages into Khmer and tailor the contents to be specific, relevant, and engaging, given the cultural context. Example messages included can be found in a previously published paper [23]."

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
Development of the message-based intervention was conducted with the support of local partners, InSTEDD iLab and the Women's Media Center (WMC). InSTEDD developed the mobile platform for interactive message delivery and data management using an open-source software program. The WMC helped translate messages into Khmer and tailor the contents to be specific, relevant, and engaging, given the cultural context. Example messages included can be found in a previously published paper [23].

We conducted a series of formative research activities using participatory methods to create appropriate and relevant health-related messages for FEWs and inform the intervention's development. The formative research process occurred over six months. We collected data through focus group discussions (FGDs), in-depth interviews (IDIs), and key informant interviews (KIIs) with the venue- and non-venue-based FEWs in addition to outreach workers and field staff that routinely work with this population [23]. Findings from the formative research revealed that FEWs were generally knowledgeable about HIV and STI prevention and transmission. However, they faced many structural barriers to optimal health, such as pressure to drink alcohol at work and complicated dynamics of negotiating condom use with clients in a criminalized environment [25, 26]. Furthermore, we found that many FEWs faced barriers to accessing medical care and services due to stigma, discrimination, and mistreatment from healthcare workers.

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).
5-iii) Does your paper address subitem 5-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

n/a

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

1 2 3 4 5
subitem not at all important □ □ □ □ □ essential
Clear selection

5-iv) Does your paper address subitem 5-iv?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"After development, the intervention underwent a four-week pilot in which 50 FEWs from each study site were randomly selected. The purpose of the pilot was to test whether the platform functioned well with the intervention design and whether the intervention was feasible and acceptable for the participants."*

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used
Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

1 2 3 4 5
subitem not at all important □ □ □ □ □ essential
Clear selection

5-v) Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The message bank is available upon request and has been given to the Ministry of Health.
5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

1 2 3 4 5
subitem not at all important 0 0 0 0 essential

Does your paper address subitem 5-vi?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1 2 3 4 5
subitem not at all important 0 0 0 0 essential

Does your paper address subitem 5-vii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A message was delivered twice a week for ten weeks, and the message from each topic area was repeated every ten weeks for 60 weeks. The health messages were framed using rights-based and health promotion frameworks. Participants could choose to receive the messages in an SMS or VM form that worked with simple and smartphone devices. Those who chose the SMS message option could further personalize their choice by selecting Khmer characters or Romanized Khmer. Each health topic message was followed by a message providing FEWs with the option to be linked to an outreach worker for free. Participants who selected this option were called by the Mobile Link’s staff, who would provide individualized information via telephone or face-to-face and, if needed, would escort the participant to services."
5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]: whether and how it is tailored to individual circumstances and allows users to track their progress and receive feedback [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

Does your paper address subitem 5-viii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the manuscript, or briefly explain why the item is not applicable/relevant for your study.

"The Mobile Link intervention was informed by both behavior change theories and extensive formative research. The intervention provided FEWs with information, resources, and reminders. By utilizing an SMS/VM platform, these services were provided in a convenient, accessible, inexpensive, and confidential manner. Therefore, we theorized that this delivery mechanism would improve FEWs’ knowledge of existing resources, risks, risk behaviors, and positive attitudes related to these topics. Increasing knowledge and positive attitudes will contribute to skill acquisition and positive behavior change."

5-ix) Describe use parameters

Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the manuscript, or briefly explain why the item is not applicable/relevant for your study.

"A message was delivered twice a week for ten weeks, and the message from each topic area was repeated every ten weeks for 60 weeks."
5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered"). It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important |  |  |  |  | essential |

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"using automated short message service (SMS) and voice messages (VM)" and "Each health topic message was followed by a message providing FEWs with the option to be linked to an outreach worker for free."

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important |  |  |  |  | essential |

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Each health topic message was followed by a message providing FEWs with the option to be linked to an outreach worker for free. Participants who selected this option were called by the Mobile Link’s staff, who would provide individualized information via telephone or face-to-face and, if needed, would escort the participant to services."

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as eHealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important |  |  |  |  | essential |
6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The primary outcome measures of the Mobile Link intervention were: (1) HIV testing, (2) STI testing when experiencing symptoms, (3) contraceptive use, (4) always use condoms with non-paying partners, and (5) always use condoms with paying partners. The secondary outcome measures were: (1) contact with outreach workers, (2) utilization of escorted referrals, (3) forced drinking at work, and (4) responses to GBV and GBV acceptance.

The primary and secondary outcomes were tracked and measured using self-reported data from the baseline, midline, and endline surveys. *

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5
subitem not at all important

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1 2 3 4 5
subitem not at all important
Does your paper address subitem 6a-ii?
Copy and paste relevant sections from manuscript text

"Participants lost to follow-up after baseline, resulting in missing outcome data at six months, were considered non-users."

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential Clear selection

Does your paper address subitem 6a-iii?
Copy and paste relevant sections from manuscript text

This information is included in the description of the formative study.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This information is presented in the Protocol adaptations section.

7a) How sample size was determined
NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size
Describe whether and how expected attrition was taken into account when calculating the sample size.

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential
Does your paper address subitem 7a–i?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The sample size was 600 based on a significance level of .05, with 80% power and accounting for 30% attrition.

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

n/a - we had no specified stopping rules.

8a) Method used to generate the random allocation sequence
NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"At each site, 60 FEWs were randomly selected using a random number generator (30 in the age group of 18–24 and 30 in the age group of 25–30) for each arm (300 FEWs in the intervention and 300 FEWs in the control arm) for a total of 600 study participants."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"At each site, 60 FEWs were randomly selected using a random number generator in a 1:1 ratio. There were 30 in the age group of 18–24 and 30 in the age group of 25–30 for each arm at each site (300 FEWs in the intervention and 300 FEWs in the control arm) for a total of 600 study participants."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned
10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Field workers developed a list of more than 4000 FEWs from the five study sites. All participants were recruited in-person at the five study sites by trained Mobile Link lay community health workers. Community health workers provided verbal information to FEWs regarding the Mobile Link’s details because of low literacy rates in this population.

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

"Recruited FEWs were assigned a unique identification number to protect their privacy and blind the researchers from their treatment arm assignment.”
11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”.

1 2 3 4 5
subitem not at all important ⬜ ⬜ ⬜ ⬜ essential

Does your paper address subitem 11a-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See informed consent form.

11b) If relevant, description of the similarity of interventions
(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

12a) Statistical methods used to compare groups for primary and secondary outcomes
NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed
"Statistical analyses

STATA/SE 15.1 (College Station, TX, USA) was used for statistical analyses. We tabulated participants’ baseline characteristics and distributions of primary and secondary outcome variables for intervention versus control arms for the analytic sample – participants with at least two observations – using frequencies and proportions for categorical variables and means and standard deviations (SDs) for continuous variables. These characteristics were compared by group using tests of association, including Pearson’s Chi-squared tests of homogeneity for categorical variables and paired Student’s t-tests for continuous variables to ensure the balance between the study arms. We conducted both crude and cluster-adjusted pooled tests of association to account for clustering within workplace venues. Participant characteristics were then compared for the analytic sample (n=388) versus non-analytic sample (n=733) to assess significant differences within and between groups for those retained in the study per protocol for at least two survey assessments (i.e., analytic sample) versus those lost to follow up after the baseline assessment (i.e., non-analytic sample).

Intervention effects were assessed using multilevel mixed-effects logistic regression to model all binary outcomes accounting for within-subject correlation from taking repeated measures on the same participants over time (two-level models with observations nested within individuals). Clustered standard errors were computed to account for the similarity of characteristics and behaviors among participants in the same venues. Separate models were conducted for each primary and secondary outcome. Model fit was assessed for each outcome using the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC).

Predictors in each simple unadjusted two-level mixed-effects logistic regression model included: group, time, and group by time interaction terms. Intervention effects for each outcome were determined by group by time interaction terms at endline with a significant p-value <0.05. Odds ratios (ORs) and 95% confidence intervals (CIs) for intervention effects at endline are displayed in Tables 2 and 3 (group by time interactions at time 3). Significant interactions indicating intervention effects were graphed using the marginsplot command (Figures 1–3). Midline effects (significant group by time interactions at time 2) are displayed in the figures but not in the tables. For the fully adjusted primary and secondary outcome models, the following covariates were included to control for alternative explanations: entertainment job venue type, province, cohabitation, age, and education. For primary outcomes, contact with outreach workers in the last six months was also included as a covariate to assess the impact of linkage support on HIV and STI testing, contraceptive use, and condom use.

As a sensitivity analysis, we used intention-to-treat (ITT) principles for modeling primary and secondary outcomes with all participants (n=1121), according to the arm to which they were assigned and then compared to the results for each outcome from the per-protocol modeling with the analytic sample. Per-protocol analyses were undertaken to assess the intervention’s impact among those who actively participated in the study. Participants lost to follow-up after baseline, resulting in missing outcome data at six months, were considered non-users. ITT and per-protocol results were consistent for all outcomes regarding the direction, strength, and significance of associations. As such, only the per-protocol
12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in eHealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Participants lost to follow-up after baseline, resulting in missing outcome data at six months, were considered non-users. ITT and per-protocol results were consistent for all outcomes regarding the direction, strength, and significance of associations. As such, only the per-protocol results are presented in the tables for ease of interpretation."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"As a sensitivity analysis, we used intention-to-treat (ITT) principles for modeling primary and secondary outcomes with all participants (n=1121), according to the arm to which they were assigned and then compared to the results for each outcome from the per-protocol modeling with the analytic sample. Per-protocol analyses were undertaken to assess the intervention’s impact among those who actively participated in the study."

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under “Methods”] (not a CONSORT item)

X26-i) Comment on ethics committee approval

Clear selection
"The Mobile Link intervention engaged community and public health stakeholders to ensure that the study incorporates best practices and strong ethical standards. Due to the sensitive nature of HIV, SRH, and GBV topics presented in the surveys and questionnaires, additional steps were taken to ensure participants’ safety and well-being. First, all data collectors received training related to asking sensitive questions. Second, upon obtaining informed consent, community health workers disclosed information, making clear the sensitive topics discussed in the data collection process. Third, participants were offered escorted referrals to counseling services and provided with services upon request. Participants could be connected to services in the event of an adverse outcome through the SMS/VM platform. Also, participants could leave the study at any time. Furthermore, participants’ identities were kept confidential and stored securely in password-protected files. Coded identifiers were given to participants after obtaining informed consent. No participants’ personal identifiers were used in analyses or report writing. Participants received $5 in compensation and transportation reimbursement for their participation. This study was approved by the National Ethics Committee for Health Research (NECHR, No. 142NECHR) within the Ministry of Health in Cambodia and the Touro College Institutional Review Board (No. PH-0117)."

x26-ii) Outline informed consent procedures
Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem X26-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Community health workers provided verbal information to FEWs regarding the Mobile Link’s details because of low literacy rates in this population. Eligible FEWs signed the informed consent form."

X26-iii) Safety and security procedures
Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Clear selection
RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

"First, all data collectors received training related to asking sensitive questions. Second, upon obtaining informed consent, community health workers disclosed information, making clear the sensitive topics discussed in the data collection process. Third, participants were offered escorted referrals to counseling services and provided with services upon request. Participants could be connected to services in the event of an adverse outcome through the SMS/VM platform. Also, participants could leave the study at any time. Furthermore, participants’ identities were kept confidential and stored securely in password-protected files. Coded identifiers were given to participants after obtaining informed consent. No participants’ personal identifiers were used in analyses or report writing. Participants received $5 in compensation and transportation reimbursement for their participation."

Does your paper address CONSORT subitem 13a? *

"Before the intervention started, 3295 FEWs were assessed for eligibility, of whom 828 FEWs did not meet the eligibility criteria, 134 declined to participate, and 325 FEWs were excluded because of other reasons. Of the included FEWs, 435 FEWs were allocated to the intervention group and 683 FEWs to the control group. By the end of 30 weeks, 217 FEWs in the intervention and 513 FEWs in the control group discontinued the study and were replaced. We included 435 FEWs in the intervention and 683 FEWs in the control group in intention-to-treat analyses and 218 FEWs in the intervention and 170 FEWs in the control group in the per-protocol analyses."

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

See CONSORT Flow Diagram
13b-i) Attrition diagram
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

4

1. subitem not at all important
2. essential

Does your paper address subitem 13b-i?
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The randomized controlled trial was conducted between March 2018 and June 2019."

14a-i) Indicate if critical “secular events” fell into the study period
Indicate if critical “secular events” fell into the study period, e.g., significant changes in Internet resources available or “changes in computer hardware or Internet delivery resources”

4

1. subitem not at all important
2. essential

Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

14b) Why the trial ended or was stopped (early)
15) Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

n/a

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group.

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Table 1 and *Participant characteristics were then compared for the analytic sample (n=388) versus non-analytic sample (n=733) to assess significant differences within and between groups for those retained in the study per protocol for at least two survey assessments (i.e., analytic sample) versus those lost to follow up after the baseline assessment (i.e., non-analytic sample).* and *We compared the characteristics of the analytic (retained) vs. non-analytic (lost to follow-up) samples and identified significant baseline differences in believing that something can be done if someone experiences abuse and forced drinking at work. Participants in the analytic sample were more likely to believe that something can be done if a person experiences abuse and to report ever being forced to drink at work. No other baseline differences were identified between analytic and non-analytic samples.*

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

1 2 3 4 5

subitem not at all important 〇 〇 〇 〇 〇 essential

Clear selection
16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

1  2  3  4  5
subitem not at all important ○ ○ ○ ○ ○ essential

Clear selection

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Tables 1-3

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

1  2  3  4  5
subitem not at all important ○ ○ ○ ○ ○ essential

Clear selection
17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address subitem 16-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"ITT and per-protocol results were consistent for all outcomes regarding the direction, strength, and significance of associations. As such, only the per-protocol results are presented in the tables for ease of interpretation."

17a-b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Tables 1-3 presents ORs and AORs

17a-i) Presentation of process outcomes such as metrics of use and intensity of use
In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

Does your paper address subitem 17a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

n/a

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Table 2 and 3 presents ORs and AORs
18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

1 2 3 4 5
subitem not at all important ○ ○ ○ ● ○ essential

Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a - non detected

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical “harm” to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. “Unintended effects” also includes unintended positive effects [2].

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ● essential

Does your paper address subitem 19-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a
Does your paper address subitem 19-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

none encountered

19-ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

| 1     | 2     | 3     | 4     | 5     |
|-------|-------|-------|-------|-------|
| subitem not at all important | 0     | 0     | 0     | ☐     |
|       |       |       |       |       | essential |

Does your paper address subitem 19-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not included in this manuscript. We have conducted a qualitative follow up study and are still processing the data.

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

| 1     | 2     | 3     | 4     | 5     |
|-------|-------|-------|-------|-------|
| subitem not at all important | 0     | 0     | 0     | ☐     |
|       |       |       |       |       | essential |

Clear selection
"Our findings suggest that the Mobile Link intervention effectively connected FEWs with outreach workers for health information and escorted referrals. However, the findings do not indicate an impact on HIV and STI testing, condom use, and contraceptive use. Reductions in forced drinking at work were significantly larger in the intervention group than in the control group."

"Our study did not detect changes in health outcomes, perhaps because these changes take longer to occur. It is also possible that several trial implementation challenges may have limited ability to detect health outcomes changes, including the high loss to follow-up, which was identified as an issue for other mHealth studies in Cambodia."

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.
21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

1) Generalisability to other populations

Generalisability to other populations: In particular, discuss generalisability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ● essential

Clear selection

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Given the positive findings on service linkages for this intervention, we will consider using the Mobile Link model with other key populations in Cambodia and the region."
21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

1  2  3  4  5
subitem not at all important  ○  ○  ○  ○  essential

Clear selection

Does your paper address subitem 21-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The traditional in-person visitation model by community health workers on two-week or monthly rotations, the standard of care during this trial, may be enhanced by interventions such as the Mobile Link." *

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NCT03117842 - Clinicaltrials.gov

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *
Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907699/pdf/13063_2018_Article_2614.pdf

25) Sources of funding and other support (such as supply of drugs), role of funders
X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated
In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |

Clear selection

Does your paper address subitem X27-i?*
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The authors declare that they have no competing interests.

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

- [ ] yes, major changes
- [x] yes, minor changes
- [ ] no

What were the most important changes you made as a result of using this checklist?

More details about recruitment and enrollment; more details about reporting methods in general.

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript? *

2 hours
As a result of using this checklist, do you think your manuscript has improved? *

- yes
- no
- Other.

Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an 'Explanation and Elaboration' document

- yes
- no
- Other.

Any other comments or questions on CONSORT EHEALTH

It would be nice to have the ability to save and come back later since this is a very long process.

STOP - Save this form as PDF before you click submit
To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select ‘print’ and then select ‘print as PDF’) before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.
Don’t worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !
Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy